Compare Apple Watch CGM apps for blood sugar readings, including Dexcom G7, FreeStyle Libre, and Eversense watch support.

Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...

DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of ...

DexCom (NasdaqGS:DXCM) reported new clinical data from its CONNECT trial on the Dexcom G7 continuous glucose monitoring system in adults with Type 2 diabetes not using insulin. The company introduced ...

Editor’s note: This post was updated on June 9 to include a statment from Pharmsource. People with diabetes who use the Dexcom G7 continuous glucose monitoring system need to check the lot numbers on ...

Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in ...

New study results could lead to better insurance coverage of the devices for people who don’t take insulin, a researcher said ...

A new study presented at the American Diabetes Association found that Dexcom’s G7 continuous glucose monitor significantly ...

Editor's note: This article has been updated with a comment from a Pharmsource spokesperson. Continuous glucose monitoring specialist Dexcom has identified two lots of Dexcom G7 sensors (1725204004 ...

Customers have known for months that the Dexcom G7 continuous glucose monitoring sensor had problems. Now, the company is ...

The upcoming system, for people with Type 1 or Type 2 diabetes ages 18 and up, boosts wear time by 50% over the currently available G7 sensor. (Dexcom) Dexcom has won a clearance from the FDA for its ...

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...